EN DE
Watch Genolution Inc. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Genolution Inc. (225220) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Genolution Inc. stock KRW 1,703, price KRW 1,744, that is 2.4% below the price, quality 42 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7225220003

GI Genolution Inc. logo Thin data Nov 16, 2026

Genolution Inc.

225220 · KQ

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Ranks above peers (7/10) 
Fair value 1,703 KRW · Fairly valued 
Quality 42/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −35.7 %/yr in KRW) 
Loss-making · -46.5% net margin (TTM) 
Negative free cash flow 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch Genolution Inc. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

9,205 KRW 1,030 KRW Fair Value 1,703 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,030 KRW – 9,205 KRW · fair‑value band 1,277 KRW – 2,129 KRW · the 1,744 KRW price screens above the 1,703 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Genolution in your weekly email

Every Wednesday you see whether Genolution is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology.

Show moreShow less

The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/RNA extraction kits.

It also develops and manufactures instruments and reagents for DNA/RNA; provides long dsRNA synthesis services; and siRNA/miRNA/shRNA synthesis service and related products. Genolution Inc. was founded in 2006 and is based in Seoul, South Korea.

Stock analysis

Genolution Inc. (225220) currently trades at 1,744 KRW, while our estimate is 1,703 KRW, so the stock looks roughly fairly valued today (gap 2.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,277 KRW (bear) to 2,129 KRW (bull), the price of 1,744 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Genolution Inc. reported revenue of 9.4B KRW in FY2025 versus 72.8B KRW in FY2021, a compound −40.1%/yr. Reported net income was −11.6B KRW in FY2025.

Key figures

Market cap 31.5B KRW (≈ $23.7M) Micro · P/S ratio 3.10 · EPS (TTM) −257.81 KRW · Net margin −46.5% · Return on equity −7.9% · Return on assets (EBIT) 6.3% (5-year average) · Operating margin −51.6% · Revenue (TTM) 10.0B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 69% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −2%, 225220 screens cheaper than that median.

Fair Value

Bear 1,277 KRW Fair Value 1,703 KRW Bull 2,129 KRW
Price 1,744 KRW · Downside -2.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 61
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Price momentum 39
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 36
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+31.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.7%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
63.4% (2020) → −91.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 225220, get fair value alerts →

Compare Genolution Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside −2.4% · Top 25%
Profitability
Return on assets −12.4% · Above median
Net margin (12 months) −46.5% · Below median
Operating margin (12 months) −51.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 7.3% · Above median
Balance sheet
Debt / equity 0.28× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.46× · Cheapest 25%
P/S (12 months) 3.14× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)30 · sector 2
FUTURE (revenue growth)37 · sector 37
PAST (return on equity)0 · sector 0
HEALTH (low debt)86 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $945.53 $1,275 +35% vs 225220
Vertex Pharmaceuticals Incorporated VRTX $536.45 $587.62 +10% vs 225220
Samsung Biologics Co 207940 1,375,000 KRW 1,502,600 KRW +9% vs 225220
argenx SE ARGX $941.25 $908.40 −3% vs 225220
CSL Limited CSL A$199.85 A$186.49 −7% vs 225220
Moderna, Inc MRNA $196.79 $135.64 −31% vs 225220
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs 225220
Revolution Medicines, Inc RVMD $159.82 $83.12 −48% vs 225220
Celltrion, Inc 068270 215,000 KRW 74,945 KRW −65% vs 225220
Royalty Pharma plc RPRX $68.67 $19.01 −72% vs 225220

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genolution Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genolution Inc. Fair Value". https://www.fairvalue-calculator.com/stock/225220

Frequently asked questions

Is Genolution Inc. (225220) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 1,703 KRW versus a price of 1,744 KRW, about 2% lower (fairly valued).
What is the fair value of 225220?
Our estimate for Genolution Inc. is 1,703 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 1,744 KRW.
What is the quality score of 225220?
Genolution Inc. has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genolution Inc. (225220)?
We do not set a price target; the yardstick is our estimate of 1,703 KRW (as of Nov 16, 2026). Cautious scenario 1,277 KRW, optimistic scenario 2,129 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Genolution Inc. stock forecast for 2026?
Our estimate puts fair value at 1,703 KRW, about 2% lower versus a price of 1,744 KRW (fairly valued). Cautious scenario 1,277 KRW, optimistic scenario 2,129 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genolution Inc. (225220)?
Genolution Inc. reported trailing-twelve-month revenue of about 10.0B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Genolution Inc. (225220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genolution Inc. it is 1,703 KRW per share (as of Nov 16, 2026), against a price of 1,744 KRW.
Is Genolution Inc. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 225220 trades above its calculated fair value: price 1,744 KRW, fair value 1,703 KRW, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 225220?
No. The price is what the market pays today (1,744 KRW); the fair value is what the company's own numbers justify (1,703 KRW). For Genolution Inc. the two are 41.04 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genolution Inc. worth?
The market values Genolution Inc. at about 31.5B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 1,744 KRW; our models calculate a fair value of 1,703 KRW per share.
What do the bullish and bearish scenarios say about 225220?
Our models span a range for Genolution Inc.: cautious scenario 1,277 KRW, base 1,703 KRW, optimistic 2,129 KRW per share (as of Nov 16, 2026, price 1,744 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genolution Inc. (225220)?
Balance-sheet figures for Genolution Inc. (as of Nov 16, 2026): return on equity −7.9%, debt of 0.28 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 225220 from its 52-week high?
Genolution Inc. trades at 1,744 KRW, about 17% below its 52-week high of 2,110 KRW and 69% above the low of 1,030 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 1,703 KRW is for.
Which stocks are comparable to Genolution Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genolution Inc. stock attractive at the current price?
The data as of Nov 16, 2026: price 1,744 KRW, calculated fair value 1,703 KRW (−2%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Genolution Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genolution Inc. (225220)?
The closing price on Nov 19, 2026 was 1,744 KRW. Our estimate is 1,703 KRW, about 2% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genolution Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Genolution Inc.

How large is the market capitalisation of Genolution Inc. (225220)?
The market capitalisation of Genolution Inc. is 31.5B KRW (≈ $23.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genolution Inc. (225220)?
The price-to-sales ratio of Genolution Inc. is 3.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genolution Inc. (225220)?
Earnings per share at Genolution Inc. are −257.81 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Genolution Inc. (225220)?
The net margin of Genolution Inc. is −46.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genolution Inc. (225220)?
The return on equity (ROE) of Genolution Inc. is −7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genolution Inc. (225220)?
On an EBIT basis the return on assets of Genolution Inc. is 6.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genolution Inc. (225220)?
The operating margin of Genolution Inc. is −51.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genolution Inc. (225220)?
Revenue at Genolution Inc. is growing 7.3% versus a year earlier (3y avg −37.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genolution Inc. (225220) generate?
The free cash flow of Genolution Inc. is −7.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genolution Inc. (225220) carry?
The net debt of Genolution Inc. is 5.1B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genolution Inc. in the live analysis

One click puts Genolution Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.